Join
Live feed
·
PRReleasevia Quantisnow
Celldex Therapeutics Inc. logo

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022

ByQuantisnow·Wall Street's wire, on your screen.
CLDX· Celldex Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLDX (Celldex Therapeutics Inc.) and more on Quantisnow.